Company Description
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific.
It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases.
It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services.
In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors.
Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
| Country | Germany |
| Founded | 2006 |
| IPO Date | Nov 7, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 444 |
| CEO | Ms. Kim Stratton |
Contact Details
Address: Am Strande 7 Rostock, 2M 18055 Germany | |
| Phone | 49 30 2130 00325 |
| Website | centogene.com |
Stock Details
| Ticker Symbol | CNTG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001757097 |
| CUSIP Number | N1976T109 |
| ISIN Number | NL0014040206 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kim Stratton | Chief Executive Officer and Member of Management Board |
| Jose Miguel Coego Rios | Chief Financial Officer, Legal and IT and Member of Management Board |
| Dr. Peter Bauer M.D. | Chief Medical and Genomic Officer and Member of Management Board |
| Dr. Andrin Oswald M.D., Ph.D. | Advisor |
| Ian Rentsch | Chief Commercial Officer and GM of Pharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Feb 29, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Jan 25, 2024 | 6-K | Report of foreign issuer |
| Jan 24, 2024 | 6-K | Report of foreign issuer |
| Jan 23, 2024 | 6-K | Report of foreign issuer |
| Jan 18, 2024 | 6-K | Report of foreign issuer |
| Dec 19, 2023 | 6-K | Report of foreign issuer |